Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 3,580,000 shares, a decline of 5.8% from the April 30th total of 3,800,000 shares. Based on an average trading volume of 598,200 shares, the […]
StockNews.com upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a sell rating to a hold rating in a report published on Monday morning. Several other brokerages also recently issued reports on BPMC. SVB Securities reduced their price objective on Blueprint Medicines from $45.00 to $38.00 in a research note on Friday, February 24th. […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) issued its quarterly earnings results on Thursday. The biotechnology company reported ($2.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.51, Briefing.com reports. The firm had revenue of $63.29 million during the quarter, compared to analyst estimates of $41.85 million. Blueprint Medicines had […]